Main menu

Small Molecule Therapeutics Discovery

Small Molecule Therapeutics Discovery

small-molecule-therapeutics-discovery

Pfizer's Worldwide Medicinal Chemistry core capabilities include small molecule design and associated functions including structural biology and computational chemistry, synthetic innovation and compound safety prediction. Our partnering strategy is designed to maintain and enhance these areas as well as generate new synergistic capabilities.

WRD is interested in establishing alliances to develop and access:

  • High content and in silico approaches to predict small molecule toxicity
  • Technology to expand NCE target space — orally bioavailable and cell penetrable peptides, and non-Ro5 compounds
  • Next generation natural product screening technology
  • Ion channel modulator design and screening technologies
  • Membrane protein structural biology technologies and capabilities
  • Small molecule computational design platforms
  • New high efficiency synthetic transformations and novel flow chemistry approaches
  • Systems biology approaches and proven in silico tools to elucidate mechanisms of in vivo toxicity
  • Systems / chemical biology technologies enabling mechanism determination for phenotypic screening hits
  • Bioinformatic approaches to define target selectivity
  • CH activation chemistry
  • Novel synthetic methodology to access small conformationally constrained multifunctional templates
  • Novel strategies for enhancing the oral bioavailability of peptides
  • Novel fragment or compound collections validated for protein-protein interaction targets
  • Identification of and access to novel sub-nanomolar cytotoxic agents
  • New chemistry to develop disease imaging agents (e.g., plaques / AD, beta cells / T2D, angiogenesis / cancer)
  • Novel methodology and capabilities to enable 18F chemistry
  • Biophysical techniques to enable rapid state dependent ion channel screening
  • Novel tissue targeting strategies

Not actively seeking partnering opportunities in:

  • De novo in silico approaches without wet lab experimental validation
  • Compound libraries with a limited track record of finding hits

R & D Brochure

callout-placeholder

Understand what R&D is looking for in an early stage opportunity.

 

Connect With Us

callout-placeholder

Reach out. We want to hear from you.